Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for WAVE Life Sciences's Days Inventory or its related term are showing as below:
WVE's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 183.195 * Ranked among companies with meaningful Days Inventory only.
WAVE Life Sciences's Days Inventory
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
WAVE Life Sciences's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.00.
WAVE Life Sciences (NAS:WVE) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
WAVE Life Sciences's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
WAVE Life Sciences's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
WAVE Life Sciences Days Inventory Related Terms
WAVE Life Sciences Days Inventory Historical Data
* Premium members only.
The historical data trend for WAVE Life Sciences's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WVE vs CGEM, LXRX, XNCR: Days Inventory Comparison
For the Biotechnology subindustry, WAVE Life Sciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Days Inventory distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (WVE) has a Days Inventory of 0.00 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on WAVE Life Sciences and its competitors. According to the industry distribution chart, WAVE Life Sciences ranks #999999 out of 638 companies in the Biotechnology industry.
Is WAVE Life Sciences' Days Inventory too high?
WAVE Life Sciences' current Days Inventory is 0.00. Based on the distribution chart, WAVE Life Sciences ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, WAVE Life Sciences has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WAVE Life Sciences' Days Inventory compare to CGEM and LXRX?
According to the Biotechnology industry distribution chart, WAVE Life Sciences ranks #999999 out of 638 companies for Days Inventory. This places WAVE Life Sciences in the lower half of its industry. The industry median Days Inventory is 183.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on WAVE Life Sciences and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WAVE Life Sciences's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WAVE Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, WAVE Life Sciences (WVE) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.36, compared to a current price of $6.13 — trading 40.6% above its estimated fair value. The current Days Inventory is 0.00. WAVE Life Sciences' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For WAVE Life Sciences (WVE), the current Days Inventory is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WAVE Life Sciences (WVE) Overvalued in 2026?
Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued.
The current stock price of $6.13 is trading 40.6% above its estimated GF Value™ of $4.36.
GuruFocus considers WAVE Life Sciences to be Significantly Overvalued.
Key valuation signals for WVE:
Days Inventory: 0.00
GF Value™: $4.36 vs. price of $6.13 (40.6% above fair value)
No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score
Get the complete analysis for WVE
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WVE has been successfully added to your 
